Key takeaways
- There is no randomized trial of GLP-1 doses below the approved starting dose for weight management, and the trials that exist show a clear dose-response: less drug, less loss.
- The 2.5 mg tirzepatide and 0.25 mg semaglutide starting doses are initiation doses in the labels, not maintenance doses; in trials they produced modest, transient loss before escalation.
- Low-dose maintenance after full-dose loss has observational support in some patients but no trial defining who, at what dose, for how long.
- Microdosing is a marketing category that lets providers price a plan below their standard plan; the price is lower because the product contains less drug, not because it is more efficient.
- We list microdose plans in our database and exclude them from rankings; a patient choosing one is choosing a protocol the trials did not test.
What providers are selling
"Microdosing" a GLP-1 means taking doses below the approved starting dose, or holding at the starting dose indefinitely, and it has become a product category in telehealth in 2025 and 2026. It is marketed for maintenance after weight loss, for "appetite control" and "food noise" in people who do not want full weight-loss doses, for fewer side effects, for longevity and inflammation, and for people whose BMI does not qualify them for the standard product. NexLife, for example, sells a microdose tirzepatide protocol at $129 to $159 per month and microdose semaglutide at $110 to $129, each $10 to $20 below its standard plans; other providers sell similar protocols under names such as "low dose," "maintenance dose" or "personalized dose." The price is lower because the vial contains less drug.
Our position, applied uniformly, is that we list these plans in the pricing database so the candidate universe is complete and exclude them from rankings, because they are protocols the trials did not test. This article explains what the evidence does and does not say.
What the dose-response trials show
The pivotal trials were designed to find doses that work, and the answer was consistent: more drug, more loss, until tolerability limits. In SURMOUNT-1, tirzepatide produced 15.0% loss at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg. The 2.5 mg dose was used only as a four-week initiation step and was not evaluated as a maintenance dose. In the semaglutide Phase 2 dose-ranging trial published in The Lancet in 2018, daily doses from 0.05 mg to 0.4 mg (roughly equivalent to weekly 0.35 mg to 2.8 mg) produced weight loss that rose steadily with dose, from about 6% at the lowest dose to about 14% at the highest, over 52 weeks, versus 2% on placebo. The STEP program then studied 2.4 mg because it was the highest well-tolerated dose. Ozempic's 0.5 mg and 1 mg diabetes doses produce roughly 4 to 6% weight loss in diabetes trials, less than half of what 2.4 mg produces in obesity.
Nothing in these data suggests a threshold below which a small dose produces a disproportionate effect. The curve is monotonic. A fraction of the starting dose would be expected to produce a fraction of the starting dose's effect, which is itself small.
The initiation dose is not a treatment dose
The labels are explicit. Zepbound's 2.5 mg is "for treatment initiation and is not intended for weight management." Wegovy's 0.25 mg is likewise an initiation dose. They exist to let the gut adapt before escalation, and in the trials the weight lost in the first four weeks at those doses was modest (typically 2 to 3%) and partly water and glycogen. Holding a patient at the initiation dose indefinitely is holding them at a dose the manufacturers and regulators explicitly did not consider therapeutic. Marketing that as a treatment for weight management is marketing an untested protocol.
Low-dose maintenance: what exists
The most defensible use of low doses is maintenance after full-dose weight loss, and here there is a real clinical question with little evidence. SURMOUNT-4 and STEP 4 established that stopping entirely causes regain of most of the loss within a year. Neither tested stepping down. Observational reports and clinical experience suggest that some patients hold their weight on a reduced dose or an extended interval, and that many drift upward and need to step back up. There is no randomized trial identifying who maintains, at what dose, or for how long, and the dose-response data imply that a lower dose defends a smaller loss.
A clinician who steps a patient down from 15 mg to 5 mg after they reach goal, monitors weight monthly, and steps back up if it rises is practising reasonable medicine in the absence of evidence. A provider that sells a "microdose maintenance" plan through a questionnaire to a patient it has never treated at full dose is selling a product. The difference is whether a clinician is making an individual decision with a plan to reverse it.
Side effects and the trade-off
Lower doses do produce fewer gastrointestinal side effects; that is the reason the titration schedule exists. A patient who cannot tolerate 5 mg of tirzepatide and can tolerate 3.75 mg has a legitimate reason for a non-standard dose, and a prescriber documenting that reason is doing what the post-shortage compounding rules require. That is dose individualization, and it is different from a marketed microdose protocol in the same way that a tailored suit is different from a small size.
"Appetite control," "food noise" and off-label goals
Some patients want less hunger without large weight loss: for maintenance, for binge eating, for a BMI that is not in the treatment range. The drugs do reduce appetite at low doses, and patients report benefit. There are no trials of GLP-1s for those goals at those doses, the labels do not cover them, and a prescription for a patient below the BMI thresholds is off-label. It is not our role to say clinicians should never do it; it is our role to say that the marketing claims attached to it have no evidence behind them, and that a patient paying $110 to $160 a month for a sub-therapeutic dose should know that.
Longevity, inflammation and the rest
Claims that microdosed GLP-1s extend lifespan, reduce inflammation independently of weight, or protect the brain rest on observational associations and animal data at full doses, extrapolated downward. The SELECT trial's cardiovascular benefit with semaglutide 2.4 mg appeared partly independent of weight loss, which is scientifically interesting and says nothing about 0.25 mg. There is no human trial of any GLP-1 at any dose for longevity.
The pricing point
Microdose plans are priced below standard plans, and the discount is proportional to the drug content, not to any efficiency. NexLife's microdose tirzepatide is $10 less per month than its standard tirzepatide at each term. A patient who chooses the microdose plan to save $120 a year is buying less of the thing that works. If the goal is to save money on an effective dose, the cheapest verified standard plan at $139 per month is the answer; if the goal is a lower dose for a documented reason, the prescription should say so.
How we treat it
Every microdose plan we know of is in the database with its price and verification status. None is ranked, and none contributes to a provider's cost score. If a randomized trial establishes a maintenance protocol below the approved doses, we will change that policy and say so on the methodology page. Until then, the evidence-based product is the standard injection at the maximum tolerated dose, and the tirzepatide and semaglutide guides describe what it does.
Frequently asked questions
Does microdosing tirzepatide or semaglutide work for weight loss?
There is no trial evidence that it does. The dose-ranging and pivotal trials show that lower doses produce less weight loss, and the approved starting doses, which are the lowest studied, produce only modest and transient loss before escalation.
Can I maintain my weight on a microdose after losing it?
Some patients report maintaining on reduced doses, and clinicians sometimes step patients down; there is no randomized trial defining a maintenance dose. The trial evidence shows that stopping entirely leads to regain, and the dose-response implies lower doses sustain smaller losses.
Why are microdose plans cheaper?
Because they contain less drug. NexLife's microdose tirzepatide plan is $10 per month less than its standard plan at each term. The saving is real; whether the product produces a result is what the evidence does not establish.
Sources
- Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022;387:205-216 (dose-response 5, 10, 15 mg).
- Frias JP et al. Efficacy and tolerability of tirzepatide, a dual GIP/GLP-1 receptor agonist, in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 2020;22:938-946.
- O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018;392:637-649.
- Zepbound and Wegovy prescribing information (initiation dose language).
- Aronne LJ et al. SURMOUNT-4. JAMA 2024;331:38-48.
- Rubino D et al. STEP 4. JAMA 2021;325:1414-1425.
- NexLife microdose tirzepatide and semaglutide program pages, nexlife.us, accessed August 25, 2026.
Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.